Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Toxicology"
DOI: 10.1177/10915818221113295
Abstract: Pretomanid is a nitroimidazooxazine antimycobacterial drug that was approved as part of a three-drug oral regimen, consisting of bedaquiline, pretomanid, and linezolid, for 6-months treatment of adults with pulmonary extensively drug-resistant tuberculosis or with complicated… read more here.
Keywords: rash2 mice; pretomanid; potential pretomanid; carcinogenic potential ... See more keywords